Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years

Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years

Abstract INTRODUCTION The evoke/evoke+ trials are investigating semaglutide in a population with early Alzheimer's disease (AD). Specific analyses of semaglutide safety data in older adults are limited; therefore, in the current analysis, we aimed to evaluate safety considerations with semaglut...

Full description

Saved in:
Bibliographic Details
Main Authors: Marwan Sabbagh, Cristina Boschini, Sharon Cohen, Magnus Fugger, Frank Jessen, Sune Dandanell, Sue D. Pedersen, Luis Rafael Solís Tarazona, Vanita R. Aroda
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
adverse event
Alzheimer's disease
early
glucagon‐like peptide‐1 analogue
pooled analysis
semaglutide
Online Access:https://doi.org/10.1002/trc2.70076
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://doi.org/10.1002/trc2.70076

Similar Items